secwatch / observer
8-K filed June 12, 2025, 7:59 PM ET ticker AIM CIK 0000946644
other material confidence high sentiment positive materiality 0.70

AIM ImmunoTech Inc. (AIM): Nasdaq/NYSE listing notice — AIM ImmunoTech completes 1-for-100 reverse split; regains NYSE American listing compliance

AIM ImmunoTech Inc.

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

AIM ImmunoTech Inc. received a nyse_american compliance regained notice regarding minimum bid price (rules 1003(f)(v)).

Exchange
nyse american
Notice
compliance regained
Deficiency
minimum bid price
Rules
1003(f)(v)
Exact text from the filing
June 11, 2025, AIM ImmunoTech Inc. (the “Company”) was notified by The NYSE American (the “Exchange”) that the Company has regained compliance with Section 1003(f)(v) of the NYSE American Company Guide (low selling price) and that trading in the Company’s Common Stock is expected to be reinstated on the Exchange on June 17, 2025 and the ticker symbol will be “AIM” upon reinstatement. The Company’s Common Stock currently trades on the OTC Pink under the symbol “AIMID”. The new CUSIP is 00901B303.
View on SEC.gov
Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

AIM ImmunoTech Inc.: Filed amendment to Articles of Incorporation effecting a 1-for-100 reverse stock split (effective 2025-06-10).

Change
charter amendment
Effective
2025-06-10
Exact text from the filing
On June 10, 2025, the Company filed an amendment to its Articles of Incorporation effecting a reverse split of its outstanding shares of Common Stock on a one for 100 basis
View on SEC.gov

5 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

AIM ImmunoTech Inc. filing history →

Source: SEC EDGAR
accession 0001641172-25-014899
Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.